spin-off

Novartis is demerging its troubled eyecare unit Alcon, most probably next year. I'm sure the spin-off would reduce Alcon's value considerably. If it was taken public, instead of the spin-off, it would have have been a much better deal, I think. It seems the new CEO has bigger plans for Novartis.